Concepedia

Scott Ackler

SA

Statistics

Publications

10

Citations

4K

H-Index

10

Active since

2002

Affiliations

Abbott Fund(Current)

AbbVie (United States)

Abbott (United Kingdom)

Abbott (United States)

Scott Ackler is an author at Abbott Fund specializing in medicine, oncology, and bcl2 inhibition.

Publications per year

2002–2015

10

Publications

10

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

, , +10

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes et al. · Clinical Cancer Research · 2008 · 209 citations

, , +12

Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · 2013 · 182 citations

, , +8

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>

Jun Chen, Sha Jin, Vivek Abraham et al. · Molecular Cancer Therapeutics · 2011 · 149 citations

, , +14

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Scott Ackler, Michael J. Mitten, Kelly Foster et al. · Cancer Chemotherapy and Pharmacology · 2010 · 121 citations

, , +12

1–5 of 10